Loading 活動
  • This event has passed.

BIO Asia International Conference

About the BIO Asia International Conference

The 15th Annual BIO Asia International Conference is an exclusive, customized partnering forum that brings together U.S. and European drug development companies with Asian biotech and pharmaceutical companies interested in research collaborations and licensing agreements.

The conference features private, pre-arranged one-on-one meetings between senior-level executives, using BIO’s proprietary, state-of-the-art computer software. The format and selective nature of the conference makes this the premier dedicated biotech partnering event in Asia and an unrivaled opportunity to meet with the leading international pharmaceutical and biotech companies in one place at one time.


Date : March 19th – March 20th, 2018

Location : Grand Hyatt Tokyo

Website : https://www.bio.org/events/bio-asia-international-conference



Tuesday, March 14, 2017

8:00 – 8:55 Networking Breakfast
8:00 – 8:55 BIO One-on-One Partnering™ Meetings
9:00  – 9:20 Welcome Remarks 
9:20 – 9:55 Opening Plenary: Seishi Baba, Parliamentary Vice-Minister of Health, Labour and Welfare
10:00 – 11:55 BIO One-on-One Partnering™ Meetings
10:00 – 11:55 Company Presentations
10:15 – 11:00 Keynote Session:
David Meeker, MD,  Executive Vice President, Sanofi and Head, Genzyme Sanofi
11:00 – 11:45 Addressing Shifts in Japanese Reimbursement Policy 
12:00  – 13:25 Luncheon Plenary – Fireside Chat:

13:30 – 17:55 BIO One-on-One Partnering™ Meetings​
13: 45 – 17:00 Company Presentations
14:00 – 14:55 Fighting Neurodegeneration: New Models for Alzheimer’s Disease and Beyond
15:00 – 15:55 Market Outlook— The Rise of Cross-Asia Partnerships
16:00 – 16:55 Update: Cancelled Session Expanding the Venture Capital Community in Asia
18:00 – 19:30 Welcome Reception 
Roppongi Hills Club

Wednesday, March 15, 2017

8:00 – 8:55 Networking Breakfast
8:00 – 11:55 BIO One-on-One Partnering™ Meetings
8:00 – 11:55 Company Presentations
9:00 – 9:45 Economic and Patient Impact of the Biomedical Research Community in Japan
9:45 – 10:30 Seeing Connections: Common Industry Growth Priorities for the Pacific Rim
10:45 – 11:40 Finding Cross-Border Clinical Trial Partners to Accelerate Approvals
12:00 – 13:25 Luncheon Plenary – Fireside Chat:
Jingsong Wang, MD, PhD, Chief Executive Officer, Harbour BioMed
13:45 -14:40 Growing Translational Research Across Asia
13:30 – 17:55 BIO One-on-One Partnering™ Meetings
13:45 – 15:30 Company Presentations


  • Joseph Damond, Senior Vice President, International Affairs, Biotechnology Innovation Organization (BIO)
  • Tim Earle, Chief Operating Officer and Chief Business Officer, TauRx Pharmaceuticals Ltd
  • Carl Firth, PhD, Founder and Chief Executive Officer, Aslan Pharmaceuticals Pte. Ltd.
  • David Flores, President and Chief Executive Officer, BioCentury Inc.
  • Kyle Hathaway, PhD, Director of Policy and Government Relations, Asia Pacific, MSD
  • Kei Katsuno, MD, MPH, Director, Investment Strategy and Development, Global Health Innovative Technology (GHIT) Fund
  • Benjamin Li, PhD, Chief Executive Officer, Lee’s Pharmaceutical Holdings Ltd.
  • Bo Liu, PhD, Principal, Venture Investments, Johnson & Johnson Innovation – JJDC, Inc.
  • Ellen Lubman, Vice President, External Science & Innovation, Allergan PLC
  • Kevin J. Lynch, PhD, Vice President, Search and Evaluation, AbbVie
  • Christopher U. Missling, PhD, President and Chief Executive Officer, Anavex Life Sciences Corp.
  • Yoko Nakata, Public & Industry Policy, Health Policy, MSD K.K.
  • Naomi Sakurai, President and Representative Director, Cancer Solutions Co., Ltd. (CANSOL)
  • Charles Stacey, MD, Chief Executive Officer, Accera
  • Yasuhiro Suzuki, MD, PhD, Director General of the Health Insurance Bureau, Ministry of Health, Labour and Welfare (MHLW), Japan
  • Yoshiaki Tsukamoto, Executive Director, Japan Bioindustry Association (JBA)
  • John Winebarger, President and Chief Executive Officer, Integrated Development Associates Co., Ltd.
  • Tatsumi Yamazaki, PhD, Chairman of the Steering Committee, Japan Bioindustry Association (JBA)
  • Jin-San Yoo, PhD, President and Chief Executive Officer, PharmAbcine Inc.
  • Zhenping Zhu, MD, PhD, President of R&D and Chief Scientific Officer, 3SBio Inc.


Statistics from 2017:

  • More than 370 delegates attended from 27 countries

  • Over 1,200 BIO One-on-One Partnering™ meetings

  • More than 230 companies represented

  • 35 innovative companies from around the world presenting their story

Why You Should Attend

  • Access to senior-level executives from leading international pharmaceutical & biotechnology companies

  • Exposure to new and exciting companies ready for partnerships and licensing opportunities in the U.S., Europe and Asia

  • Tremendous networking opportunities to meet numerous U.S., European, Japanese and Asian biotech and pharmaceutical companies in one place at one time

  • Use of state-of-the-art partnering technology

  • Targeted partner selections through proprietary screening process

  • Private meetings scheduled by BIO

  • Informative plenary sessions

Who Should Attend

  • Drug development and discovery companies

  • Medical technology companies

  • Universities and institutes

  • Intellectual property and legal organizations

  • Investors and financial services providers

  • Bio-clusters and incubators

  • Government and public support agencies